AGTC Applied Genetic Technologies Dashboard

Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Company profile

Ticker

AGTC

Exchange

NASDAQ

Website

www.agtc.com/

CEO

Susan Washer

Incorporated

Delaware

Location

Florida

Fiscal year end

Jun 30

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...

SEC CIK

0001273636

Corporate docs

Articles of Incorporation & Bylaws

AGTC stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Applied Genetic Tech Q3 EPS $(0.40) Beats $(0.41) Estimate

17 May 21

Applied Genetic Tech (NASDAQ:AGTC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 20 percent increase over losses of $(0.50) per share from

Earnings Scheduled For May 17, 2021

17 May 21

Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter.

Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows

14 May 21

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

14 May 21

Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity

6 May 21

Press releases

Pro users get this 30m faster

Applied Genetic Technologies Corp. to Host Earnings Call

17 May 21

NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Applied Genetic Technologies Corp. (NASDAQ:AGTC) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 17, 2021 at 4:30 PM

Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation Park

14 May 21

GAINESVILLE, Fla., May 14, 2021 /PRNewswire/ -- Concept Companies, a Gainesville headquartered full-service real estate development and construction firm, has executed an agreement to commence development of a new

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

14 May 21

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept

AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates

13 May 21

AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021

11 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

17 May 21

18 May 21

30 Jun 21

Financial summary

Financial statements Chart AGTC financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 20	Jun 19	Jun 18	Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	89.53M	89.53M	89.53M	89.53M	89.53M	89.53M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	4.83M	4.94M	3.81M	4.29M
Cash used (since last report)	n/a	n/a	7.67M	7.84M	6.05M	6.81M
Cash remaining	n/a	n/a	81.87M	81.69M	83.48M	82.72M
Runway (months of cash)	n/a	n/a	17.0	16.5	21.9	19.3

Beta Read what these cash burn values mean

Recent insider trades

AGTC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 20	Koenig Scott	Stock Option Common Stock	Grant	Aquire A	No	No	4.72	12,000	56.64K	12,000
16 Dec 20	Aliski William	Stock Option Common Stock	Grant	Aquire A	No	No	4.72	12,000	56.64K	12,000
16 Dec 20	Hurwitz Edward	Stock Option Common Stock	Grant	Aquire A	No	No	4.72	12,000	56.64K	12,000
16 Dec 20	Magovcevic Ivana	Stock Option Common Stock	Grant	Aquire A	No	No	4.72	12,000	56.64K	12,000
16 Dec 20	James Rosen	Stock Option Common Stock	Grant	Aquire A	No	No	4.72	12,000	56.64K	12,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AGTC institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

40.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	72	72	–
Opened positions	11	13	-15.4%
Closed positions	11	9	+22.2%
Increased positions	22	17	+29.4%
Reduced positions	19	25	-24.0%

13F shares	Current	Prev Q	Change
Total value	91.23M	100.84M	-9.5%
Total shares	17.36M	15.17M	+14.4%
Total puts	15.3K	23.6K	-35.2%
Total calls	243.7K	284.8K	-14.4%
Total put/call ratio	0.1	0.1	-24.2%

Largest owners	Shares	Value	Change
BLK Blackrock	1.73M	$7.08M	+7.1%
Interwest Partners Viii	1.4M	$5.74M	NEW
Interwest Venture Management	1.4M	$5.74M	-3.5%
Portolan Capital Management	1.31M	$5.35M	+0.5%
Intersouth Partners Vi	1.21M	$4.97M	NEW
Renaissance Technologies	1.02M	$4.16M	-4.9%
Vanguard	971.28K	$3.97M	+3.3%
Dimensional Fund Advisors	943.38K	$3.86M	-0.3%
DAFNA Capital Management	903.43K	$3.7M	-17.5%
Millennium Management	717.36K	$2.93M	+16.4%

Largest transactions	Shares	Bought/sold	Change
Interwest Partners Viii	1.4M	+1.4M	NEW
Intersouth Partners Vi	1.21M	+1.21M	NEW
Sofinnova Investments	0	-825.07K	EXIT
Integrated Core Strategies	717.36K	+717.36K	NEW
Assenagon Asset Management	220.05K	-224.88K	-50.5%
DAFNA Capital Management	903.43K	-191.71K	-17.5%
683 Capital Management	175K	-189.3K	-52.0%
Pura Vida Investments	0	-176.41K	EXIT
Colony	116.59K	+116.59K	NEW
BLK Blackrock	1.73M	+114.22K	+7.1%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Biogen • Adverum Biotechnologies • Benitec Biopharma • Allergan • Regenxbio • Spark Therapeutics • Voyager Therapeutics • Editas Medicine • Nightstar Therapeutics • Prevail Therapeutics

Management Discussion

The table below summarizes our research and development expenses by product candidate or program for the periods indicated.
External research and development expenses consist of collaboration, licensing, manufacturing, testing and other miscellaneous costs that are directly attributable to our most advanced product candidates and discovery programs. We do not allocate employee-related
costs, including share-based compensation, costs associated with broad technology platform improvements or other indirect costs, to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as internal research and development expenses in the table above.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abovementioned, Academy, Adelphi, adjacent, advisory, aforementioned, American, appointed, April, Bayer, BCVA, Cantor, care, cGMP, chain, COBRA, commence, commencement, commencing, construction, core, Corrected, coverage, customary, demonstrate, detachable, Director, discretionary, Distinguishing, dividend, double, durability, eligible, enable, extension, eye, fabrication, family, firm, fit, Fitzgerald, foot, footage, freestanding, Gartner, gave, genomic, Gerald, healthcare, homebuilder, hospital, Index, inflammation, inflammatory, instate, Island, joining, landlord, launch, lifestyle, luxury, medical, medicine, mutual, nonexclusive, ocular, OfferingSM, ophthalmic, owner, Park, people, President, prorated, recruit, redundancy, resigning, response, responsible, return, SAS, serve, served, shell, shown, single, southeastern, SparingVision, staffing, statistically, story, strategy, strict, Sullivan, supply, Susan, taxation, tenant, Terrace, Treasurer, twenty, uncollected, unexercised, unvested, Vice, Washer, WCI, William

Removed: adrenoleukodystrophy, ALD, dosing, estimation, placement, relate, revise

From filing 10-Q 2021 Q3